Nuclear Medicine Advances in Breast Cancer Imaging
- 1 September 2001
- journal article
- review article
- Published by SAGE Publications in Tumori Journal
- Vol. 87 (5) , 277-287
- https://doi.org/10.1177/030089160108700501
Abstract
Primary breast cancer imaging can be done by various means. Mammography is the most widely used technique because of its excellent diagnostic performance, patient compliance, and cost-effectiveness ratio. Other radiological techniques (such as ultrasonography) are indicated in particular circumstances, while some (such as digital mammography and magnetic resonance imaging) seem very promising but are still under evaluation. The recent technological progress in nuclear medicine has resulted in the availability of two diagnostic procedures that have been validated by extensive international clinical experience: scintimammography with Ses-ta-MIBI and positron emission tomography (PET) with fluorodeoxyglucose (FDG). The general advantage of nuclear medicine imaging is that tumor-seeking radiopharmaceuticals accumulate in cancer lesions, which makes scintimammography and PET fundamentally different from the radiological techniques that image the tumor mainly on the basis of morphological alterations. Scintimammography is indicated for the study of breast lesions in patients in whom mammography is non-diagnostic or difficult to interpret; it may be useful also to assess and even predict the response to primary chemotherapy. FDG-PET is increasingly used in oncology and is particularly useful in breast cancer as it gives more accurate information than scintimammography in the evaluation of patients with ambiguous mammographies and in discriminating between viable tumor, fibrotic scar or necrosis following surgery, chemo- or radiotherapy. The FDG uptake in the tumor correlates with the histological grade and potential aggressiveness of breast cancer, which may have prognostic implications. In addition to its usefulness in the study of breast lesions, FDG-PET shows great efficacy in detecting lymph node involvement prior to surgery. Whole-body PET provides information on soft tissue and bone metastases in a single scanning session, and has an important clinical role in detecting recurrent metastatic disease. On the basis of the above-mentioned evidence, nuclear medicine techniques, integrated with radiological techniques, offer an interesting opportunity to improve the diagnostic imaging yield in breast cancer, which will eventually lead to better patient management. This paper reports on the latest developments in this field.Keywords
This publication has 55 references indexed in Scilit:
- Breast CancerPublished by Springer Nature ,1999
- Cancer imaging: principles and practicePublished by Springer Nature ,1998
- Scintimammography (Smm) with 99mTc-Mdp: An Overview of the Experience at the National Cancer Institute of NapoliTumori Journal, 1997
- Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucoseEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- Technetium-99m sestamibi: an indicator of breast cancer invasivenessEuropean Journal of Nuclear Medicine and Molecular Imaging, 1994
- Review of imaging techniques for the diagnosis of breast cancer: a new role of prone scintimammography using technetium-99m sestamibiEuropean Journal of Nuclear Medicine and Molecular Imaging, 1994
- Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast CarcinomaNew England Journal of Medicine, 1991
- 201Tl scintigraphy in the staging of lung cancer, breast cancer and lymphornaNuclear Medicine Communications, 1990
- Clinical Experience of Tumor Imaging with 201TI-ChlorideClinical Nuclear Medicine, 1977
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975